Shao Lee Lin
Director/Board Member at SURROZEN, INC.
Net worth: 15 M $ as of 2024-04-29
Profile
Shao Lee Lin was the founder of ACELYRIN, Inc. (founded in 2020) where they held the title of Chief Executive Officer & Director.
Dr. Lin's current jobs include being a Director at Surrozen Operating, Inc. (since 2021) and an Independent Director at Surrozen, Inc. (since 2021).
Dr. Lin's former jobs include being a Director at Principia Biopharma, Inc. (2019-2020), an Independent Director at Third Harmonic Bio, Inc. (2020-2023), VP-Inflammation & Respiratory Development at Gilead Sciences, Inc. (2012-2015), VP-Therapeutic Areas & Development Excellence at AbbVie, Inc. (2015-2017), Chief Scientific Officer, EVP, Head-R&D at Horizon Therapeutics Plc (2018-2020), and a Trustee at Lake Forest College (2018-2020).
Dr. Lin's education includes an undergraduate degree from Rice University and a doctorate from The Johns Hopkins University School of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ACELYRIN, INC.
3.49% | 2024-03-31 | 3,452,329 ( 3.49% ) | 15 M $ | 2024-04-29 |
Shao Lee Lin active positions
| Companies | Position | Start |
|---|---|---|
| SURROZEN, INC. | Director/Board Member | 2020-12-31 |
Surrozen Operating, Inc.
 Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Director/Board Member | 2021-02-01 |
Former positions of Shao Lee Lin
| Companies | Position | End |
|---|---|---|
| ACELYRIN, INC. | Founder | 2024-05-07 |
| THIRD HARMONIC BIO, INC. | Director/Board Member | 2023-01-16 |
| PRINCIPIA BIOPHARMA INC. | Director/Board Member | 2020-09-27 |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Chief Tech/Sci/R&D Officer | 2020-01-22 |
| Lake Forest College | Director/Board Member | 2019-12-31 |
Training of Shao Lee Lin
| The Johns Hopkins University School of Medicine | Doctorate Degree |
| Rice University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| ABBVIE INC. | Health Technology |
| GILEAD SCIENCES, INC. | Health Technology |
| ACELYRIN, INC. | Health Technology |
| SURROZEN, INC. | Health Technology |
| THIRD HARMONIC BIO, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
Principia Biopharma, Inc.
 Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. | Health Technology |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Shao Lee Lin
